Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,175.33 +18.47 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 569,824
Open 1,167.31
Bid (Size) 1,150.00 (1)
Ask (Size) 1,880.67 (2)
Prev. Close 1,156.86
Today's Range 1,155.31 - 1,177.95
52wk Range 769.19 - 1,177.95
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Stocks That Usually Benefit From a Recession
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession. 
Via InvestorPlace
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga

Performance

YTD
+29.87%
+29.87%
1 Month
+8.61%
+8.61%
3 Month
+20.15%
+20.15%
6 Month
+24.00%
+24.00%
1 Year
+45.84%
+45.84%

More News

Read More
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Via InvestorPlace
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
Via Benzinga
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Via InvestorPlace
Exposures Product Safety
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
3 Healthcare Stocks Positioned for Possible Market Outperformance
Via InvestorPlace
Is Regeneron Pharmaceuticals Due for a Stock Split?
Via The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Via Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
Via Investor's Business Daily
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Via Benzinga
Regeneron Reports Second Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Via Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Via Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Via Benzinga
3 Standout Stocks to Buy for the Next Bull Market
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.